LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, ...

The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant ...

Ghoreifi works with the House Staff and is a part of Duke Urologic Oncology Fellowship, Duke Urology, at Duke School of Medicine, located in Durham, North Caroline.

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing non–muscle-invasive bladder cancer.

Four years after remission from follicular lymphoma, ongoing fear of relapse, lingering symptoms, and life stressors continue ...

CM24 plus Opdivo and chemo improved survival in pancreatic cancer with CEACAM1 biomarkers, supporting a biomarker-driven ...

Investigators shared real-world data showing a clear and consistent association between increased tumor size and mortality ...

A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid ...

Sinai, Urology, located in Los Angeles, including professor; associate director, Urology Residency Training Program; chair, Department of Urology; co-medical director, Urologic Oncology Center; and ...

Dr. Hyung L. Kim discusses how the addition of cytoreductive nephrectomy to ICI therapy may affect survival and quality of ...

A chance meeting with my childhood friend reminded me — and others— that living with cancer means taking things one day at a ...

The FDA has granted approval to treatment with Tepylute, a ready-to-dilute version of thiotepa, at 100 mg for breast and ...